PT  - JOURNAL ARTICLE
AU  - Jolee Potts
AU  - Rachel Raven Lee
AU  - Carolyn A Hilliard
TI  - Lichenoid dermatitis preceding Stevens-Johnson syndrome in a patient treated with nivolumab
AID  - 10.1136/bcr-2022-251233
DP  - 2022 Aug 01
TA  - BMJ Case Reports
PG  - e251233
VI  - 15
IP  - 8
4099  - http://casereports.bmj.com/content/15/8/e251233.short
4100  - http://casereports.bmj.com/content/15/8/e251233.full
SO  - BMJ Case Reports2022 Aug 01; 15
AB  - Nivolumab is an immune checkpoint inhibitor acting on programmed cell death protein 1 (PD-1) that has been used to treat a growing number of malignancies. Cutaneous side effects are common with nivolumab treatment, though they are typically self-limited. Here we present a case of persistent lichenoid dermatitis in a patient treated with nivolumab for renal cell cancer. The patient then developed Stevens-Johnson syndrome 9 months after initiation of nivolumab, with no other identifiable offending medication in the interim. Although an unusual presentation, a growing number of cases have reported delayed Stevens-Johnson syndrome/toxic epidermolytic necrosis-like reactions to immune checkpoint inhibitors. Awareness of this phenomenon is imperative for prompt recognition and treatment of potentially life-threatening cutaneous side effects.